This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Buy Teleflex (TFX) Ahead of Earnings?
by Zacks Equity Research
Teleflex (TFX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for Pacific Biosciences' (PACB) Q2 Earnings?
by Zacks Equity Research
Pacific Biosciences' (PACB) flagship Sequel System is likely to drive Q2 results; competition is a headwind.
Can Kidney Care Business Drive DaVita's (DVA) Q2 Earnings?
by Zacks Equity Research
DaVita's (DVA) flagship Kidney Care business likely to drive Q2 results; solid international presence encourages.
Can R&D Focus Drive DENTSPLY SIRONA's (XRAY) Q2 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) continued focus on research and development and strategic buyouts are likely to drive Q2 results.
What's in Store for Cerner (CERN) This Earnings Season?
by Zacks Equity Research
Cerner's (CERN) Q2 results are likely to show softer performance owing to declining revenues across core business segments.
What's in Store for AmerisourceBergen (ABC) in Q3 Earnings?
by Zacks Equity Research
AmerisourceBergen's (ABC) Q3 results are likely to be driven by its core Pharmaceutical Distribution business; a competitive industry is a headwind.
Can BD Medical Drive Becton, Dickinson's (BDX) Q3 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) core BD Medical likely to register solid results in Q3; a possible decline in BD Life Sciences raises concern.
Can Business Services Aid athenahealth's (ATHN) Q2 Earnings?
by Zacks Equity Research
athenahealth's (ATHN) core Business Services unit is likely to drive growth in Q2; the company's focus on cloud-based services is encouraging.
Should Pacer Trendpilot US Mid Cap ETF (PTMC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PTMC
Should Pacer Trendpilot US Mid Cap ETF (PTMC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PTMC
Medical Products Stock Earnings on May 3: BDX, CAH & More
by Zacks Equity Research
Given the solid prospects of the U.S. medical products industry, here we take a look at four major Medical Product companies scheduled to report results on May 3.
DaVIta (DVA) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Kidney Care Business and increasing number of dialysis centers are likely to boost DaVita's (DVA) earnings in Q1.
What's in the Cards for Inogen (INGN) This Earnings Season?
by Zacks Equity Research
Inherent benefits of POCs, direct-to-customer business model, underpenetrated international markets and expanding product portfolio are key growth catalysts for Inogen (INGN) in Q1.
What's in Store for AmerisourceBergen (ABC) in Q2 Earnings?
by Zacks Equity Research
Despite solid prospects in the Pharmaceutical Distribution segment, a temporary slowdown in the PharMEDium unit is likely to mar AmerisourceBergen's (ABC) Q2 earnings.
Can PBM Unit Boost Express Scripts' (ESRX) Q1 Earnings?
by Zacks Equity Research
Impressive performance by the PBM unit is likely to drive Express Scripts' (ESRX) Q1 earnings.
Will Global Industrial Unit Boost Ecolab's (ECL) Q1 Earnings?
by Zacks Equity Research
Solid prospects in Global Industrial, Global Energy and Global Institutional segments are likely to drive Ecolab's (ECL) Q1 earnings.
Can Business Services Aid athenahealth's (ATHN) Q1 Earnings?
by Zacks Equity Research
athenahealth's (ATHN) strong product portfolio, network expansion strategies and unique business model are likely to drive Q1 earnings.
4 MedTech Stocks to Keep in Good Books This Earnings Season
by Zacks Equity Research
Considering the ageing population, changing market dynamics, upbeat consumer sentiment and increased business investments, the Medical-Device sector appears to be in pink of health.
Here's Why Teleflex Has Been Losing Ground Since Q4 Earnings
by Zacks Equity Research
Teleflex's (TFX) contracted Q4 adjusted operating margin is discouraging.
Teleflex (TFX), HealthTrust Rebond on Respiratory Products
by Zacks Equity Research
Teleflex's (TFX) exclusive contracts with HealthTrust provide benefits to the latter with an opportunity to consolidate its members' respiratory purchases with the same supplier.
Key MedTech Trends to Influence Q3 Earnings: BDX, ABC, TFX
by Zacks Equity Research
Here we take a look at the major factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe this season.
Should You Buy Teleflex (TFX) Ahead of Earnings?
by Zacks Equity Research
Teleflex (TFX) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Teleflex (TFX) Hits a 52-Week High on NeoTract Acquisition
by Zacks Equity Research
NeoTract acquisition is expected to generate mid-single digit constant currency revenue growth for the next several years and enhance Teleflex's (TFX) margins.
Abiomed's Latest Regulatory Progress Boosts Impella Line
by Zacks Equity Research
We believe that robust demand for Impella products will continue to drive Abiomed's (ABMD) top line over the long term.
Top Ranked Momentum Stocks to Buy for September 21st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 21st: